Navigation Links
Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
Date:4/20/2009

Renowned Physicians Join World Class Group of Advisors

SAN DIEGO, April 20 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the expansion of its Clinical Advisory Board, naming Donald H. Batts, MD, FACP, FIDSA, and G. Ralph Corey, MD, as the sixth and seventh members of the group of anti-infective thought leaders. Dr. Batts is a Professor of Medicine at Michigan State University and the Chief of Infectious Diseases at its Kalamazoo Campus. Dr. Corey is the Gary Hock Distinguished Professor of Global Health and the Director of the Hubert/Yeargan Center for Global Health and Director of Infectious Disease Research at the Duke Clinical Research Institute.

"Don and Ralph bring years of academic and industry experience to the Advisory Board that will benefit us as we advance torezolid into Phase 3 development," said Philippe Prokocimer, MD, Chief Medical Officer of Trius. "Collectively, their clinical development of anti-infectives has contributed to the approval of several important new drugs."

"Torezolid is one of the most compelling antibacterial drugs in the clinic so I look forward to advising Trius on its continued development," said Dr. Batts, who was lead investigator at the Upjohn Company for the development of linezolid, the sole marketed antibiotic in the oxazolidinone class.

"I look forward to working closely with Dr. Prokocimer and the rest of the Trius team to help develop the clinical and regulatory strategy for torezolid as it moves into Phase 3 testing," said Dr. Corey.

"The guidance that these distinguished clinicians provide will be critical not only for torezolid as it transitions into Phase 3 testing, but also for our preclinical programs as we advance them toward Phase 1 testing," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "Our goal is to provide patients and physicians best-in-class therapeutic options to address the growing unmet need for safe and effective treatments for drug resistant bacterial infections in the hospital and in the community."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has licensed worldwide rights outside of Korea to torezolid from Dong-A Pharmaceuticals. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Trius Awarded $28 Million Contract to Develop Novel Antibiotics
2. Trius Appoints Paul Truex to Board of Directors
3. Ventus Medical Appoints John McCutcheon as President and CEO
4. Sinobiopharma, Inc. Appoints New Director of Marketing
5. Yongye Biotechnology Appoints New Chief Financial Officer
6. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
7. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
8. BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer
9. MacroGenics Appoints New Vice President of Business Development
10. DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors
11. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... ... talent development and compliance training, today announced an interactive FDA compliance training ... The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now ...
(Date:2/4/2016)... SHENZHEN, China , Feb. 4, 2016 ... government, and various medical institutions attended a ceremony in ... provide integrative, personalized cell therapy in 2016. ... the "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" ... Shenzhen Regional Cell Production Center, both subsidiaries of Beike ...
(Date:2/4/2016)... Feb. 4, 2016  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today provided an update ... the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings that ... The IPR was initiated on only certain claims of ...
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
(Date:2/2/2016)... VIEW, Calif. , Feb. 2, 2016 /PRNewswire/ ... retinopathy market, Frost & Sullivan recognizes US-based Intelligent ... America Frost & Sullivan Award for New Product ... provider in North America , ... in the rapidly growing diabetic retinopathy market. The ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. a ... West Chester, Ohio announced today ... service staff, based in Austin, Texas ... ability to provide modifications, installations and technical support offerings ... CEO of PLUS, commented, "PLUS has provided world class ...
Breaking Biology News(10 mins):